title: The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.
abstract: Molecular-targeted therapy against tyrosine kinase receptors (RTKs) plays an important role in gastric cancer (GC) treatment. Understanding the correlation between RTK coexpression could better guide clinical drug use. In the present study, the coexpression status of c-MET, fibroblast growth factor receptor 2 (FGFR2), and human epidermal growth factor receptor 2 (HER2) in human GC and their clinical significance in clinical therapy were explored. Immunohistochemical (IHC) staining, quantitative real-time polymerase chain reaction and fluorescent in situ hybridization were performed in 143 cases of GC who had undergone gastrectomy without preoperative chemoradiotherapy. Their association with clinicopathological features and clinical prognosis was analyzed. The frequencies of c-MET, FGFR2, and HER2 overexpression were 47.6% (68/143), 34.3% (49/143), and 10.5% (15/143), respectively. In the RTK coexpression study, 30.1% of patients (43/143) were positive for only one RTK, 25.8% (37/143) were positive for two RTKs, 3.5% (5/143) had triple-positive status, and 40.6% (58/143) had triple-negative status. In survival analysis, the overexpression of c-MET, FGFR2, and HER2 were significantly associated with overall survival (OS) (P=0.018, 0.004, and 0.049, respectively). In coexpression analysis, patients with triple-positive GC had the poorest OS (P=0.013). In conclusion, RTK coexpression is significantly associated with poor clinical outcome in GC.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University; Esophageal and Gastric Cancer Center of Henan Province.
authors.forename: Yong-Xu
authors.initials: YX
authors.lastname: Jia
authors.affiliation: Department of Interventional Radiology.
authors.forename: Teng-Fei
authors.initials: TF
authors.lastname: Li
authors.affiliation: Department of Pathology.
authors.forename: Dan-Dan
authors.initials: DD
authors.lastname: Zhang
authors.affiliation: Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University.
authors.forename: Zong-Min
authors.initials: ZM
authors.lastname: Fan
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University; Esophageal and Gastric Cancer Center of Henan Province.
authors.forename: Hui-Jie
authors.initials: HJ
authors.lastname: Fan
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University; Esophageal and Gastric Cancer Center of Henan Province.
authors.forename: Jie
authors.initials: J
authors.lastname: Yan
authors.affiliation: Department of Oncology, Tumor Hospital of Henan Province, Zhengzhou, Henan, People's Republic of China.
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Chen
authors.affiliation: Department of Oncology, Tumor Hospital of Henan Province, Zhengzhou, Henan, People's Republic of China.
authors.forename: Hong
authors.initials: H
authors.lastname: Tang
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University; Esophageal and Gastric Cancer Center of Henan Province.
authors.forename: Yan-Ru
authors.initials: YR
authors.lastname: Qin
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University.
authors.forename: Xing-Ya
authors.initials: XY
authors.lastname: Li
keywords: FGFR2; HER2; c-MET; coexpression; gastric cancer; survival; target therapy